Evidence map›Paper›PMID 26981134›Full record

ArticleStem cells international2016

Transcatheter Arterial Infusion of Autologous CD133(+) Cells for Diabetic Peripheral Artery Disease.

Xiaoping Zhang, Weishuai Lian, Wensheng Lou, Shilong Han, Chenhui Lu, Keqiang Zuo, Haobo Su, Jichong Xu, Chuanwu Cao, Tao Tang and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Xiaoping ZhangDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China; Institution of Interventional and Vascular Surgery, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Weishuai LianDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Wensheng LouDepartment of Interventional Radiology, Nanjing First Hospital, No. 68 Changle Road, Nanjing, Jiangsu 210001, China.
Shilong HanDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Chenhui LuDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Keqiang ZuoDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Haobo SuDepartment of Interventional Radiology, Nanjing First Hospital, No. 68 Changle Road, Nanjing, Jiangsu 210001, China.
Jichong XuDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Chuanwu CaoDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Tao TangDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Zhongzhi JiaDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Tao JinDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Georges UzanUnité de Recherche INSERM 602, 94807 Villejuif Cedex, France.
Jianping GuDepartment of Interventional Radiology, Nanjing First Hospital, No. 68 Changle Road, Nanjing, Jiangsu 210001, China.
Maoquan LiDepartment of Interventional and Vascular Surgery, Shanghai Tenth People's Hospital, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China; Institution of Interventional and Vascular Surgery, Tongji University, No. 301 Middle Yan Chang Road, Shanghai 200072, China.
Shanghai Tenth People's Hospital · CNTongji University · CNNanjing Medical University · CNInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microvascular lesion in diabetic peripheral arterial disease (PAD) still cannot be resolved by current surgical and interventional technique. Endothelial cells have the therapeutic potential to cure microvascular lesion. To evaluate the efficacy and immune-regulatory impact of intra-arterial infusion of autologous CD133(+) cells, we recruited 53 patients with diabetic PAD (27 of CD133(+) group and 26 of control group). CD133(+) cells enriched from patients' PB-MNCs were reinfused intra-arterially. The ulcer healing followed up till 18 months was 100% (3/3) in CD133(+) group and 60% (3/5) in control group. The amputation rate was 0 (0/27) in CD133(+) group and 11.54% (3/26) in control group. Compared with the control group, TcPO2 and ABI showed obvious improvement at 18 months and significant increasing VEGF and decreasing IL-6 level in the CD133(+) group within 4 weeks. A reducing trend of proangiogenesis and anti-inflammatory regulation function at 4 weeks after the cells infusion was also found. These results indicated that autologous CD133(+) cell treatment can effectively improve the perfusion of morbid limb and exert proangiogenesis and anti-inflammatory immune-regulatory impacts by paracrine on tissue microenvironment. The CD133(+) progenitor cell therapy may be repeated at a fixed interval according to cell life span and immune-regulatory function.

Identifiers

PMID26981134
PMCPMC4769775
OpenAlexW2274136254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.